Introduction Lumateperone is an oral atypical antipsychotic marketed under the brand name Caplyta. It is used in adults for schizophrenia, depressive episodes associated with bipolar I or bipolar II disorder, and as adjunctive therapy with antidepressants for major depressive disorder. The current U.S. prescribing information lists the recommended Caplyta dose as 42 mg orally once … Read more
Introduction Rexulti is the brand name of brexpiprazole, an oral atypical antipsychotic used in psychiatric and neuropsychiatric conditions. Pharmacologically, brexpiprazole is a serotonin-dopamine activity modulator with partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors, along with antagonist activity at serotonin 5-HT2A receptors. Rexulti is used as adjunctive therapy with antidepressants for major depressive … Read more
Introduction Vraylar is the brand name of cariprazine, an oral atypical antipsychotic used in schizophrenia, bipolar I disorder, and major depressive disorder as adjunctive therapy. Current prescribing information lists Vraylar for schizophrenia in adults and pediatric patients 13 years and older, acute manic or mixed episodes associated with bipolar I disorder in adults and pediatric … Read more
Introduction Caplyta is the brand name of lumateperone, an oral atypical antipsychotic used in adults for schizophrenia, depressive episodes associated with bipolar I or bipolar II disorder, and as adjunctive treatment with an antidepressant for major depressive disorder. It is not known whether Caplyta is safe and effective in children. Caplyta is important in pharmacology … Read more
